- GlobeNewswire•3 days agoFinal CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials Submission of marketing applications to regulatory authorities expected in third quarter of 2017. BRUSSELS, Belgium and MENLO ...
- PR Newswire•last monthAmgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan
THOUSAND OAKS, Calif. and BRUSSELS, Dec. 19, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that an application seeking marketing approval of romosozumab for the treatment of osteoporosis for those at high risk of fracture has been submitted for review to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Amgen and UCB are co-developing romosozumab worldwide, with development in Japan being led by Amgen Astellas BioPharma (AABP) K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.
- MarketWatch•last month
European stocks gain Friday, with drugmaker shares showing strength, as the Stoxx Europe 600 notches its highest close of the year.
UCB.BR : Summary for UCB - Yahoo Finance
UCB S.A. (UCB.BR)
Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
|Bid||64.00 x 203800|
|Ask||66.00 x 10000|
|Day's Range||62.70 - 63.86|
|52 Week Range||54.84 - 85.12|
|PE Ratio (TTM)||18.35|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|